{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:58:57Z","timestamp":1787504337885,"version":"build-2736575974"},"reference-count":32,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2017,7,27]],"date-time":"2017-07-27T00:00:00Z","timestamp":1501113600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Bundesministerium f\u00fcr Bildung und Forschung (DE)","award":["01GI0925"],"award-info":[{"award-number":["01GI0925"]}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["STE 1096\/3-1"],"award-info":[{"award-number":["STE 1096\/3-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0181880","type":"journal-article","created":{"date-parts":[[2017,7,27]],"date-time":"2017-07-27T13:53:10Z","timestamp":1501163590000},"page":"e0181880","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":21,"title":["DPP4 gene variation affects GLP-1 secretion, insulin secretion, and glucose tolerance in humans with high body adiposity"],"prefix":"10.1371","volume":"12","author":[{"given":"Anja","family":"B\u00f6hm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fausto","family":"Machicao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens Juul","family":"Holst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baptist","family":"Gallwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Stefan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Fritsche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Ulrich","family":"H\u00e4ring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9507-5333","authenticated-orcid":true,"given":"Harald","family":"Staiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,7,27]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/713609354","article-title":"Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV","volume":"40","author":"AM Lambeir","year":"2003","journal-title":"Crit Rev Clin Lab Sci"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0065-1281(87)80049-1","article-title":"Dipeptidyl peptidase IV (DP IV), a functional marker of the T lymphocyte system","volume":"82","author":"S Ansorge","year":"1987","journal-title":"Acta Histochem"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0167-0115(99)00089-0","article-title":"Dipeptidyl-peptidase IV (CD26)\u2014role in the inactivation of regulatory peptides","volume":"85","author":"R Mentlein","year":"1999","journal-title":"Regul Pept"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1055\/s-2004-826160","article-title":"Circulation and degradation of GIP and GLP-1","volume":"36","author":"CF Deacon","year":"2004","journal-title":"Horm Metab Res"},{"key":"ref5","first-page":"333","article-title":"Distribution of proline-specific aminopeptidases in human tissues and body fluids","volume":"30","author":"G Vanhoof","year":"1992","journal-title":"Eur J Clin Chem Clin Biochem"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.2174\/092986709788803114","article-title":"Dipeptidyl peptidase-4 (CD26): knowing the function before inhibiting the enzyme","volume":"16","author":"E Matteucci","year":"2009","journal-title":"Curr Med Chem"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1006\/bbrc.2001.4999","article-title":"Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptidyl peptidase IV-deficient Fischer rats","volume":"284","author":"T Nagakura","year":"2001","journal-title":"Biochem Biophys Res Commun"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0024-3205(02)01637-5","article-title":"Improvement of high fat-diet-induced insulin resistance in dipeptidyl peptidase IV-deficient Fischer rats","volume":"71","author":"N Yasuda","year":"2002","journal-title":"Life Sci"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"6825","DOI":"10.1073\/pnas.0631828100","article-title":"Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance","volume":"100","author":"SL Conarello","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s11892-008-0031-0","article-title":"Beta-cell failure in type 2 diabetes mellitus","volume":"8","author":"C Lencioni","year":"2008","journal-title":"Curr Diab Rep"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1210\/er.2009-0017","article-title":"Pathomechanisms of type 2 diabetes genes","volume":"30","author":"H Staiger","year":"2009","journal-title":"Endocr Rev"},{"key":"ref12","first-page":"S20","article-title":"Novel incretin-based agents and practical regimens to meet needs and treatment goals of patients with type 2 diabetes mellitus","volume":"111","author":"AJ Garber","year":"2011","journal-title":"J Am Osteopath Assoc"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.2165\/11592810-000000000-00000","article-title":"Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: current and emerging agents","volume":"71","author":"B Gallwitz","year":"2011","journal-title":"Drugs"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1517\/13543784.2011.576667","article-title":"Small molecule dipeptidylpeptidase IV inhibitors under investigation for diabetes mellitus therapy","volume":"20","author":"B Gallwitz","year":"2011","journal-title":"Expert Opin Investig Drugs"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/dmrr.1184","article-title":"Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials","volume":"27","author":"M Monami","year":"2011","journal-title":"Diabetes Metab Res Rev"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1016\/S0140-6736(12)60439-5","article-title":"Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial","volume":"379","author":"P Aschner","year":"2012","journal-title":"Lancet"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.trsl.2011.09.005","article-title":"Serum level of soluble CD26\/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and\/or sulfonylurea","volume":"159","author":"Y Aso","year":"2012","journal-title":"Transl Res"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1007\/s00125-005-1948-3","article-title":"Polymorphisms in the gene encoding adiponectin receptor 1 are associated with insulin resistance and high liver fat","volume":"48","author":"N Stefan","year":"2005","journal-title":"Diabetologia"},{"key":"ref19","first-page":"952","article-title":"Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo","volume":"80","author":"CF Deacon","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"ref20","first-page":"3575","article-title":"Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide","volume":"85","author":"CF Deacon","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.2337\/diacare.22.9.1462","article-title":"Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp","volume":"22","author":"M Matsuda","year":"1999","journal-title":"Diabetes Care"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"e14194","DOI":"10.1371\/journal.pone.0014194","article-title":"Evaluation of fasting state-\/oral glucose tolerance test-derived measures of insulin release for the detection of genetically impaired beta-cell function","volume":"5","author":"SA Herzberg-Schafer","year":"2010","journal-title":"PLoS One"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.2337\/db10-1707","article-title":"Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome","volume":"60","author":"D Lamers","year":"2011","journal-title":"Diabetes"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"E372","DOI":"10.1152\/ajpendo.00319.2010","article-title":"Altered dipeptidyl peptidase-4 activity during the progression of hyperinsulinemic obesity and islet atrophy in spontaneously late-stage type 2 diabetic rats","volume":"300","author":"Y Kirino","year":"2011","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1515\/JPEM.2010.23.1-2.101","article-title":"Changes of dipeptidyl peptidase IV (DPP-IV) in obese children with weight loss: relationships to peptide YY, pancreatic peptide, and insulin sensitivity","volume":"23","author":"T Reinehr","year":"2010","journal-title":"J Pediatr Endocrinol Metab"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1210\/jc.2009-2054","article-title":"Secretion and dipeptidyl peptidase-4-mediated metabolism of incretin hormones after a mixed meal or glucose ingestion in obese compared to lean, nondiabetic men","volume":"95","author":"RD Carr","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1507\/endocrj.EJ12-0158","article-title":"Plasma dipeptidyl peptidase 4 activity correlates with body mass index and the plasma adiponectin concentration in healthy young people","volume":"59","author":"Y Kirino","year":"2012","journal-title":"Endocr J"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.2337\/db07-1315","article-title":"Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients","volume":"57","author":"E Muscelli","year":"2008","journal-title":"Diabetes"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1210\/jcem.86.8.7750","article-title":"Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients","volume":"86","author":"MB Toft-Nielsen","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00592-008-0049-4","article-title":"Comprehensive genetic analysis of the dipeptidyl peptidase-4 gene and cardiovascular disease risk factors in obese individuals","volume":"46","author":"L Bouchard","year":"2009","journal-title":"Acta Diabetol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s13300-012-0008-5","article-title":"Impact of insulin resistance, body mass index, disease duration, and duration of metformin use on the efficacy of vildagliptin","volume":"3","author":"A Schweizer","year":"2012","journal-title":"Diabetes Ther"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.amjmed.2010.11.002","article-title":"Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications","volume":"124","author":"MA Nauck","year":"2011","journal-title":"Am J Med"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0181880","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,24]],"date-time":"2018-10-24T00:07:26Z","timestamp":1540339646000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0181880"}},"subtitle":[],"editor":[{"given":"Massimo","family":"Pietropaolo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,7,27]]},"references-count":32,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2017,7,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0181880","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,27]]}}}